September 28, 2022
Alkermes Announces Launch of 5th Annual Alkermes Pathways Research Awards® Program
September 20, 2022
Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress
July 27, 2022
Alkermes plc Reports Second Quarter 2022 Financial Results
Alkermes worked with The Harris Poll to gather psychiatrists’ insights and perspectives on caring for people living with bipolar I disorder.
Congratulations to Kanchan Relwani, M.D., Head of Medical Affairs, for being recognized as our 2022 Healthcare Businesswomen’s Association Luminary – a testament to her role as a mentor and leader.
Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.